- Home
- DKNG vs NTRA Comparison
DKNG vs NTRA Comparison
Compare DKNG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DKNG | NTRA |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 32.9B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DKNG | NTRA |
|---|---|---|
| Price | $25.00 | $196.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 29 | 14 |
| Target Price | $41.41 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 13.5M | 1.1M |
| Earning Date | 05-15-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.05 | 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,054,525,000.00 | $210,939,000.00 |
| Revenue This Year | $15.75 | $16.65 |
| Revenue Next Year | $12.94 | $19.22 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.99 | N/A |
| 52 Week Low | $21.01 | $125.38 |
| 52 Week High | $48.78 | $256.36 |
Technical Indicators
Market Signals| Indicator | DKNG | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.35 | 42.73 |
| Support Level | $25.01 | $194.03 |
| Resistance Level | $36.46 | $251.09 |
| Average True Range (ATR) | 1.06 | 8.26 |
| MACD | 0.46 | -0.55 |
| Stochastic Oscillator | 66.47 | 36.05 |
Price Performance
Historical ComparisonAbout DKNG DraftKings Inc.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. DraftKings is now live with online or retail sports betting in 28 states and i-gaming in 5 states, with both products available to around 40% of Canada's population. In 2024, sports revenue was 61% of total sales, i-gaming 32%, and fantasy and lottery 7%. The company plans to launch a predictive event platform in late 2025 and also operates a non-fungible token commission-based marketplace and develops and licenses online gaming products.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.